Website Search
ID 15082
Shutting down cancer with Gleevec, Brian Druker
Description:
Interviewee: Brian Druker.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
(DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Shutting down cancer)
Transcript:
If you look back at the history of cancer research, in many respects for 30 or 40 years we've been stumbling around in the dark. We understood that cancer is probably a genetic disease but what those genetic abnormalities are that caused the uncontrolled growth of cancer in most cases remain elusive. With Gleevec we've shown that if you understand what drives the growth of a cancer you can shut it down specifically.
Keywords:
chronic myeloid leukemia,causes of cancer,gleevec,location applications,genetic abnormalities,dnai,cancer research,uncontrolled growth,genetic disease,cml,interviewee,leukemia,brian druker,genes,respects,medicine
Downloads:
This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.Related content:
- 15057. Before and after Gleevec, Brian Druker
- Brian Druker talks about the drug he developed as a turning point in the war on cancer.
- SOURCE: DNAi
- 15055. Using DNA science to control CML, Brian Druker
- Brian Druker talks about how the drug he designed targets the molecular cause of CML.
- SOURCE: DNAi
- 15054. Restoring hope with Gleevec, Brian Druker
- Brian Druker talks about how Gleevec has restored patients' hope for the future.
- SOURCE: DNAi
- 15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
- View the animation to find out how the drug Gleevec⢠inhibits the molecular cause of chronic myeloid leukemia.
- SOURCE: DNAi
- 15056. Approval for Gleevec in record time, Brian Druker
- Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
- SOURCE: DNAi
- 15712. Bud and Yvonne
- Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
- SOURCE: DNAi
- 15042. The first day of clinical trials for Gleevec, Bud and Yvonne
- Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
- SOURCE: DNAi
- 15041. Getting the diagnosis of chronic myeloid leukemia, Bud
- Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
- SOURCE: DNAi
- 15714. Brian Druker
- Brian Druker is a professor at Oregon Health Sciences University.
- SOURCE: DNAi
- 1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
- Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
- SOURCE: IC
